Artikel ; Online: Promising Lead Compounds in the Development of Potential Clinical Drug Candidate for Drug-Resistant Tuberculosis.
Molecules (Basel, Switzerland)
2020 Band 25, Heft 23
Abstract: According to WHO report, globally about 10 million active tuberculosis cases, resulting in about 1.6 million deaths, further aggravated by drug-resistant tuberculosis and/or comorbidities with HIV and diabetes are present. Incomplete therapeutic regimen, ...
Abstract | According to WHO report, globally about 10 million active tuberculosis cases, resulting in about 1.6 million deaths, further aggravated by drug-resistant tuberculosis and/or comorbidities with HIV and diabetes are present. Incomplete therapeutic regimen, meager dosing, and the capability of the latent and/or active state tubercular bacilli to abide and do survive against contemporary first-line and second line antitubercular drugs escalate the prevalence of drug-resistant tuberculosis. As a better understanding of tuberculosis, microanatomy has discovered an extended range of new promising antitubercular targets and diagnostic biomarkers. However, there are still no new approved antitubercular drugs of routine therapy for several decades, except for bedaquiline, delamanid, and pretomanid approved tentatively. Despite this, innovative methods are also urgently needed to find potential new antitubercular drug candidates, which potentially decimate both latent state and active state |
---|---|
Mesh-Begriff(e) | Animals ; Antitubercular Agents/pharmacology ; Coumarins/chemistry ; Drug Design ; Humans ; Isoniazid/chemistry ; Mycobacterium tuberculosis/drug effects ; Peptides, Cyclic/chemistry ; Pharmaceutical Preparations/administration & dosage ; Pharmaceutical Preparations/chemistry ; Pore Forming Cytotoxic Proteins/chemistry ; Tuberculosis, Multidrug-Resistant/drug therapy ; Tuberculosis, Multidrug-Resistant/microbiology |
Chemische Substanzen | Antitubercular Agents ; Coumarins ; Peptides, Cyclic ; Pharmaceutical Preparations ; Pore Forming Cytotoxic Proteins ; griselimycin ; coumarin (A4VZ22K1WT) ; Isoniazid (V83O1VOZ8L) |
Sprache | Englisch |
Erscheinungsdatum | 2020-12-02 |
Erscheinungsland | Switzerland |
Dokumenttyp | Journal Article ; Review |
ZDB-ID | 1413402-0 |
ISSN | 1420-3049 ; 1431-5165 ; 1420-3049 |
ISSN (online) | 1420-3049 |
ISSN | 1431-5165 ; 1420-3049 |
DOI | 10.3390/molecules25235685 |
Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
Zs.MO 81: Hefte anzeigen |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.